Acquisitions
Acquisitions completed from the 2022 financial year are distributed among the group’s business areas as follows:
| Acquisitions | Time | Net Sales, SEKm* | Number of employees* | Business area |
|---|---|---|---|---|
| MBA Incorporado S.L, Spain | January, 2022 | 670 | 285 | Medtech |
| Business from Telia Health Monitoring, Sweden | March, 2022 | 4 | 8 | Medtech |
| O’Flynn Medical Ltd, Ireland | April, 2022 | 64 | 36 | Medtech |
| BioCat GmbH, Germany | April, 2022 | 90 | 20 | Labtech |
| JK Lab Nordic AB, Sweden | July, 2022 | 24 | 6 | Labtech |
| Emmat Medical Ltd, Great Britain | September, 2023 | 28 | 4 | Medtech |
| 880 | 359 | |||
| * Refers to conditions at the time of acquisition on a full-year basis. | ||||
During the interim period, one acquisition has been completed.
On September 1 2023, AddLife acquired all shares in the company Emmat Medical Ltd for the Medtech business area. Emmat is active in surgical products in Great Britain and has a turnover of approximately SEK 28 m and has four employees. The company is integrated into the Healthcare 21 Group.
Revaluation of liabilities for contingent considerations regarding previous acquisitions has resulted in income of SEK 100 m of which SEK 82 m relates to the acquisition of AddVision and SEK 15 m relates to the acquisition of Bio-Connect. During the interim period, this has been reversed and reported in other operating income. Contingent considerations amounted to SEK 16 m have been paid during the interim period regarding Ropox, which was acquired in 2020.